Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Core Insights - Sapu Nano has received approval from Australia's Human Research Ethics Committee to begin a Phase 1 clinical trial for Sapu003, an injectable form of Everolimus aimed at treating breast cancer [1][3] - The injectable Sapu003 utilizes Deciparticle™ technology to deliver 100% of the drug into the bloodstream, overcoming the limitations of the oral form, which only allows about 10% absorption [2][4] - The trial aims to address the unmet need for more effective mTOR inhibitors, as current therapies often provide less than one year of progression-free survival [3] Company Overview - Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications [5] - The company holds a 45% stake in GMP Bio, a joint venture that is advancing its own pipeline of drug candidates, enhancing Oncotelic's strategic position in oncology and rare disease therapeutics [6]